Skip to main content
Equibles
PIII logo

PIII · P3 Health Partners Inc. · Metrics

Track PIII — free

Use PIII with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PIII.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.36 +0.25 (+6.08%) At close · Oct 22
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of the date of this Form 10-Q, we believe that our existing cash resources are not sufficient to support planned operations for at least the next year from the issuance of the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$31.66M
Shares
7.26M
Volume · Oct 22 11.31K Avg daily vol (3M) 32.83K

PIII metrics

75 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.36
Market cap
$31.66M

Price action

20 metrics
Price change (1W)
+5.3%
Price change (30D)
-42.0%
Price change (3M)
-53.2%
Price change (6M)
+60.6%
Price change (YTD)
+24.9%
Price change (1Y)
-50.4%
Trailing year
Price change (5Y)
—
52-week high
$16.47
52-week low
$1.52
Change from 52-week high
-73.5%
Change from 52-week low
+186.8%
Annualized volatility
219.5%
Annualized volatility (3M)
73.1%
Beta
-1.5
RSI (14D)
30.0
Price vs SMA 50
-42.1%
Price vs SMA 200
-33.1%
Avg volume (3M)
32,829
Relative volume
0.3
Average dollar volume
$338,857

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
7.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.1×
reciprocal yield 1,170.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 5,035.9%
P / book
0.4
reciprocal yield 245.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-329.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.2×
reciprocal yield 506.3%
EV / revenue historical average (5Y)
0.3×
reciprocal yield 374.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
—
Operating margin
-9.9%
Trailing 12 months
Net margin
-6.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$148.63M
Net income (TTM)
−$98.44M
Trailing 12 months
Diluted EPS (TTM)
$-33.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$383.77
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-47.19
EBITDA per diluted share (TTM)
$-25.59
Net income per diluted share (TTM)
$-30.32
Operating cash flow per diluted share (TTM)
$-34.24
Free cash flow per diluted share (TTM)
$-36.48
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$1.09
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+8.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.50B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.9%
Year over year · more shares
Revenue CAGR (3Y)
+11.6%
Revenue CAGR (5Y)
+24.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-134.5%
Return on assets
-15.0%
Debt / equity
1.6
Current ratio
0.5
EBITDA (TTM)
−$64.48M
Free cash flow (TTM)
—
Quick ratio
0.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$98.58M
Latest balance sheet
Cash & equivalents
$21.27M
Total assets
$654.39M
Total debt
$119.85M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$130.52M
Capital expenditures (TTM)
$119,000
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$4.23M
R&D / revenue
—
Stock compensation / revenue
0.3%

Ownership (13F)

9 metrics
13F filers
35
13F filer change QoQ
0
Institutional ownership
68.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+90.4%
Holder tenure
3.6
Price vs estimated holder cost
+26.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
22 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1832511 CUSIP 744413204 13F (30d) 1 filings 1 filers Visit website Investor relations